Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

Knight Therapeutics Inc TSX: GUD-T

Today's Change
Volume
Real-Time Last Update TSX Last Sale

Today's Trading

Day Low 4.95
Day High 5.15
Open:5.04
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Description
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research.

Moderate Buy

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

ValuEngine

A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Latest Press Releases

Knight Therapeutics Announces Canadian Commercial Launch of IBSRELA(TM) - New Innovative Treatment for Irritable Bowel Syndrome with Constipation
- GlobeNewswire - Mon Mar 1, 6:04PM CST
GlobeNewswire - CMTX
Mon Mar 1, 6:04PM CST
Knight Therapeutics Inc. (TSX: GUD), ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today the Canadian commercial availability of IBSRELA (tenapanor), a first-in-class therapy for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. Knight has the exclusive right to commercialize IBSRELA in Canada under the terms of a license agreement entered into with Ardelyx, Inc. (NASDAQ: ARDX) in March 2018, which license agreement also provides Knight with exclusive rights to commercialize tenapanor for hyperphosphatemia in Canada. IBSRELA was approved by Health Canada on April 15, 2020 and is now covered by most private insurance companies in Canada.
Knight Announces Filing of Final Base Shelf Prospectus
- GlobeNewswire - Wed Dec 23, 5:08PM CST
GlobeNewswire - CMTX
Wed Dec 23, 5:08PM CST
Knight Therapeutics Inc. (TSX: GUD) ("Knight") today has filed and has obtained a receipt for a (final) short form base shelf prospectus (the "Shelf Prospectus"). The Shelf Prospectus was filed with the securities regulatory authorities in each of the provinces of Canada and enables Knight to offer for sale and issue up to $360 million of common shares of Knight ("Common Shares"), subscription receipts of Knight (the "Subscription Receipts") and debt securities of Knight (the "Debt Securities", and collectively with the Common Shares and the Subscription Receipts, the "Securities") from time to time during the 25-month period during which the Shelf Prospectus remains valid. The specific variable terms of any offering of Common Shares, Subscription Receipts or Debt Securities will be set forth in one or more prospectus supplements.
S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite Index
- CNW Group - Fri Dec 11, 4:15PM CST
CNW Group - CMTX
Fri Dec 11, 4:15PM CST
S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite Index
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 4.88 +5.53% increase
on 03/04/21
Period Open:5.44
Price movement based on the high, low and last over the given period.
5.77 -10.75% decrease
on 02/11/21
-0.29 (-5.33%) decrease
since 02/05/21
3-Month 4.88 +5.53% increase
on 03/04/21
Period Open:5.28
Price movement based on the high, low and last over the given period.
5.86 -12.12% decrease
on 01/20/21
-0.13 (-2.46%) decrease
since 12/04/20
52-Week 4.73 +8.88% increase
on 03/19/20
Period Open:6.92
Price movement based on the high, low and last over the given period.
8.08 -36.26% decrease
on 04/24/20
-1.77 (-25.58%) decrease
since 03/05/20

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2021.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

© 2021 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies